Genprex (Genprex) EBIT : $-27.81 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Genprex EBIT?

Genprex's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-6.00 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-27.81 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Genprex's annualized ROC % for the quarter that ended in Mar. 2024 was -480.34%. Genprex's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -399,800.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Genprex's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 904.26%.

Genprex EBIT Historical Data

The historical data trend for Genprex's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genprex EBIT Chart

Genprex Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-10.68

-17.96

-20.67

-23.83

-31.08

Genprex Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-9.27	-8.04	-7.79	-5.99	-6.00

Competitive Comparison of Genprex's EBIT

For the Biotechnology subindustry, Genprex's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genprex's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genprex's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genprex's EV-to-EBIT falls into.

Genprex EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.81 Mil.

Genprex (NAS:GNPX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Genprex's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-23.988 * ( 1 - 0% )	/	( (4.995	+	4.993)	/ 2 )
=	-23.988	/	4.994
=	-480.34 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.671	-	1.398	-	( 6.738	-	max(0, 3.254	-	7.532	+	6.738	))
=	4.995

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	12.565	-	2.152	-	( 8.217	-	max(0, 3.808	-	9.228	+	8.217	))
=	4.993

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Genprex's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-23.988	/	( ( (0.008 + max(-2.46, 0))	+	(0.004 + max(-2.797, 0)) )	/	2 )
=	-23.988	/	( ( 0.008	+	0.004 )	/	2 )
=	-23.988	/	0.006
=	-399,800.00 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.794)	-	(1.398	+	0	+	1.856)
=	-2.46

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.011)	-	(2.152	+	0	+	1.656)
=	-2.797

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Genprex's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-27.806	/	-3.075
	=	904.26 %

Genprex EBIT Related Terms

Thank you for viewing the detailed overview of Genprex's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Genprex (Genprex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genprex Inc (NAS:GNPX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

2DE:Germany

Address

3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746

Website

https://www.genprex.com

Genprex Inc is a clinical-stage gene therapy company. It is a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.

Executives

Catherine M Vaczy	officer: EVP & Chief Strategy Officer	C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
John Rodney Varner	director, 10 percent owner, officer: Chief Executive Officer	P.O. BOX 162341, AUSTIN TX 78716
Hermant Kumar	officer: Chief Mfgr & Tech Officer	3300 BEE CAVE ROAD, #650-227, AUSTIN TX 78746
Mark Stanley Berger	officer: Chief Medical Officer	140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Brent M Longnecker	director	C/O RESOURCES CONNECTION, 695 TOWN CENTER DR, COSTA MESA CA 92626
Moreno Toscano Jose Antonio	director	1501 UNIVERSITY CLUB DRIVE, AUSTIN TX 78732
Wilson William R Jr.	director	1407 ETHRIDGE AVE, AUSTIN TX 78703
Michael Thomas Redman	officer: EVP & Chief Operating Officer	16402 EMILIA COURT, SPRING TX 77379
John N Bonfiglio	director	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Genprex, Inc.	director, 10 percent owner, officer: Chief Executive Officer	1601 TRINITY STREET, BLDG. B, SUITE 3.322, AUSTIN TX 78712
Julien L Pham	officer: Chief Operating Officer	944 DORCHESTER AVE #56, BOSTON MA 02125
Jack A Roth	10 percent owner	6516 BROMPTON ROAD, HOUSTON TX 770055
Christy M. Nance	10 percent owner	8305 SCENIC RIDGE COVE, AUSTIN TX 78735
Ryan M. Confer	officer: Chief Financial Officer	1000 SAN MARCOS ST. #460, AUSTIN TX 78702
Robert W. Pearson	director	3001 MEANDERING RIVER COURT, AUSTIN TX 78746